HL Mando and HL Klemove Jointly Participate in CES 2025

HL Heroes Video Revealed with the Slogan "Envision the Future"

Showcasing Innovations such as HAECHIE, BEETLE+, and AgriShield

SEOUL, South Korea and LAS VEGAS , Jan. 7, 2025 /PRNewswire/ -- HL Group, along with its global SDV leader HL Mando Corp. and autonomous driving solution specialist HL Klemove Corp. will jointly participate in the world's largest IT exhibition, CES 2025, from January 7 to 10. Under the slogan "Envision the Future," the two companies will showcase comprehensive autonomous driving solutions that extend beyond mobility, presented in a multi-level cube booth. The booth is designed with an additional upper floor, reserved as a VIP meeting room, on top of the floor for general visitors.

The exhibition floor is divided into four sections. The Intro Zone, which sets the stage with the theme "Leader of Automotive Solution," will introduce the two companies' past achievements and future business ventures. In the Autonomous Parking & Driving Zone, visitors will have the chance to experience a screen game featuring PARKIE, the parking robot that won last year's Best Innovation Award. Additionally, the autonomous shuttle HOCKEY will also be featured. The *HL Heroes Show will take the center stage in the main zone. The video is scheduled to be shown five times a day, featuring a cartoon style with five retro-styled characters. It showcases the ambitious retro cartoon graphics developed by HL Mando and HL Klemove. In the Urban Mobility Zone, various smart personal mobility (SPM) solutions will be on display, including HL Mando's Steerite Fit (an electric signal steering technology) and chainless two-wheelers and three-wheelers.

Innovation Award Zone will feature three products which received CES Innovation Award:  HAECHIE by HL Mando, BEETLE+ by HL Klemove, and AgriShield. HAECHIE was awarded in the Human Security For All category. It detects electrical sparks faster than traditional heat or smoke-based detection methods, with sensitivity more than 100 times greater than existing products. As an advanced electrical fire prevention solution, HL Mando's HAECHIE is expected to see broad use across diverse industries, including electric vehicles, charging stations, energy storage systems (ESS), and data centers. BEETLE+, awarded in the Smart Cities category, is a portable radar developed by HL Klemove, a leader in autonomous driving solutions. Renowned for its high performance, it has a detection range of 30 meters and enhanced forward detection capabilities. When BEETLE+ detects obstacles in both the front and rear, it immediately alerts users to the location and risk level of the obstacles via a dedicated mobile app. AgriShield is a state-of-the-art wildlife deterrent device, often referred to as a "smart scarecrow." This product can distinguish between wildlife, such as wild boars and water deer, and humans. Equipped with Vision AI Algorithms, it reflects the developers' ambitious vision. Recognized for its potential to address the global issues of wildlife damage, AgriShield was awarded in the Industrial Equipment & Machinery category.

HL Mando CEO Seong-hyeon Cho commented, "Building on over 60 years of accumulated technological expertise, HL has integrated the value of safety into this CES exhibition through autonomous driving, SDV, mobility, robotics, and sensors," emphasizing the significance of their participation.

The HL Mando and HL Klemove joint booth will be located at Las Vegas Convention Center West Hall, Booth No. 5352. A variety of events are planned during CES, including a strategic partnership signing ceremony with HARMAN.

*HL Heroes Show

In a single retro cartoon video, HL's cutting-edge technologies transform into heroic characters, much like the Avengers. This production was created to make the two companies more relatable to the public. As descried by the marketing strategy team, the concept of "technology as the hero safeguarding everyday safety" is embedded in the content, modernizing the traditional retro slogan, "Technology by Mando." The video begins with HAECHIE. HACHIE detects an arc (an electrical spark), an early warning sign of an electrical fire. The patrol robot GOALIE then sends an alert, while the parking robot PARKIE swiftly relocates vehicles to clear access routes. The work-assist robot MiCKIE observes and assesses the situation, and finally, the autonomous shuttle HOCKEY rescues people.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

HL Mando and HL Klemove Jointly Participate in CES 2025

HL Mando and HL Klemove Jointly Participate in CES 2025

YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with Toripalimab in treating locally advanced or metastatic urothelial carcinoma (la/mUC) (NCT04264936, study ID: RC48-C014). This trial was supervised by Professor Jun Guo and Professor Xi'nan Sheng's teams from Peking University Cancer Hospital.

It is the first time that long-term follow-up data has been released for a HER2-targeted antibody-drug conjugate (ADC) and PD-1 inhibitor combination therapy in treating la/mUC, marking it a significant milestone. The nearly-three-year follow-up data revealed an objective response rate (ORR) of 73.2% and median overall survival (OS) of 33.1 months, superior to data published from any other prospective clinical studies on ADC plus PD-1 combination therapies for la/mUC.

New Treatment Options for Patients with La/mUC

UC is the sixth most common cancer worldwide. GLOBOCAN 2022 estimated the year 2021 saw 614,298 new cases and 220,596 deaths of UC. In recent years, the prognosis for patients with la/mUC has significantly improved with new drugs and combination therapies approved, among which ADCs demonstrated outstanding potential.

As a HER2-targeted ADC, DV has been approved in China for patients with HER2-overexpressing (defined as immunohistochemistry [IHC] test results of 2+ or 3+) la/mUC previously treated with platinum-containing chemotherapy. The approval is based on the pooled results of two studies (NCT03507166 and NCT03809013, study IDs: RC48-C005 and RC48-C009) where the ORR registered 50.5% and the median duration of response (DOR) registered 7.3 months.

Multiple clinical studies on la/mUCin recent years have confirmed the synergistic antitumor effects of ADC combined with immunotherapy. NCT04264936 offered stronger evidence as its long-term follow-up results published in the Annals of Oncology demonstrated the high response rate, significant survival benefits, and manageable safety profile of the DV and Toripalimab combination therapy.

DV Combined with Toripalimab: High Response Rate and Prolonged Survival

NCT04264936 is an open-label, multicenter, investigator-initiated phase 1b/2 clinical trial investigating the safety and efficacy of DV in combination with Toripalimab for the treatment of patients with HER2-expressing la/mUC. The dose-escalation study (phase 1b) assessed two dose levels of DV (1.5 and 2.0 mg/kg) combined with Toripalimab (3.0 mg/kg) to determine the recommended phase 2 dose which was then evaluated in the dose-expansion stage (phase 2).

From August 2020 to December 2021, 41 patients were enrolled with a median age of 66 years. 53.7% of the participants were male, 70.7% had an ECOG performance status score of 1, 17 (41.5%) had lung metastasis, and 10 (24.4%) had liver metastasis.

As of March 1, 2024, among all participants, the ORR was 73.2% with 4 (9.8%) achieving complete response and 26 (63.4%) achieving partial response, the DCR was 90.2%, the median progression-free survival (PFS) was 9.3 months, the median DOR was 8.6 months, the median OS was 33.1 months and the 36-month OS rate was 49.2%.

Subgroup analysis revealed ORR benefits across all subgroups regardless of the number of prior lines of systemic treatments, HER2 expression (IHC 1+/2+/3+), and PD-L1 expression status. The ORRs for chemotherapy-naïve patients and those who progressed on platinum-based chemotherapy were 76.0% (19/25) and 68.8% (11/16), respectively. The ORRs for patients with HER2 IHC 3+, 2+, 1+, or 0 were 80.0%, 84.2%, 64.3%, and 33.3%, respectively. Compared with the three HER2 IHC 0 participants (one of whom achieved partial response), those with HER2 expression (IHC 1+/2+/3+) had a higher ORR (76.3% vs 33.3%) and longer PFS (median PFS: 9.3 vs 1.7 months).

In summary, the DV and Toripalimab combination therapy has preliminarily demonstrated promising efficacy and manageable safety profile among patients with la/mUC, wherein those with HER2 expression (IHC 1+/2+/3+) achieved high response rates and long-term survival benefits. These findings support the further exploration and validation of the benefits of DV combined with PD-1 inhibitors in treating la/mUC.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma